Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Phase-I, Double-Blind, Placebo-Controlled, Dose-Escalation (Single Ascending Dose) Study And Multiple Ascending Dose (Dose-Escalation) Study To Evaluate Safety, Tolerability & Pharmacokinetics of HRF-10071 Tablet of Hetero Labs Limited, India In Normal, Healthy, Adult, Human Male Subjects Under Fasting/Fed Condition And Evaluation of Food Effect With One Cohort of Single Ascending Dose

Next Previous
Search
Trial Profile

A Randomized, Phase-I, Double-Blind, Placebo-Controlled, Dose-Escalation (Single Ascending Dose) Study And Multiple Ascending Dose (Dose-Escalation) Study To Evaluate Safety, Tolerability & Pharmacokinetics of HRF-10071 Tablet of Hetero Labs Limited, India In Normal, Healthy, Adult, Human Male Subjects Under Fasting/Fed Condition And Evaluation of Food Effect With One Cohort of Single Ascending Dose

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Nov 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HRF-10071 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Hetero Drugs

    • Most Recent Events

    • 30 Nov 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top